UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 28, 2008
OR
TRANSITION REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition
period from________to_______
COMMISSION FILE
NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235
East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip
code)
(212) 573-2323
(Registrant's telephone number)
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.
YES X NO
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company. See definitions of "large accelerated filer," "accelerated
filer" and "smaller reporting company" in Rule 12b-2 of the
Exchange Act (Check one):
Large accelerated filer X Accelerated
filer Non-accelerated
filer Smaller
reporting company
Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).
YES NO X
At November 4, 2008, 6,742,935,405 shares of the
issuer's voting common stock were outstanding.
FORM 10-Q
For the Quarter
Ended
September 28, 2008
Table
of Contents
PART I. FINANCIAL
INFORMATION
Page
Item 1.
Financial Statements
Condensed
Consolidated Statements of Income for the three months and nine months ended September 28,
2008, and September 30, 2007
Condensed
Consolidated Balance Sheets as of September 28, 2008, and December 31,
2007
Condensed
Consolidated Statements of Cash Flows for the nine months ended September 28,
2008, and September 30, 2007
Notes to
Condensed Consolidated Financial Statements
Review Report
of Independent Registered Public Accounting Firm
18
Item 2.
Management's
Discussion and Analysis of Financial Condition and Results of Operations
19
Item 3.
Quantitative
and Qualitative Disclosures About Market Risk
50
Item 4.
Controls and
Procedures
50
PART II. OTHER
INFORMATION
Item 1.
Legal
Proceedings
51
Item 1A.
Risk Factors
53
Item 2.
Unregistered
Sales of Equity Securities and Use of Proceeds
54
Item 3.
Defaults Upon
Senior Securities
54
Item 4.
Submission of
Matters to a Vote of Security Holders
54
Item 5.
Other
Information
54
Item 6.
Exhibits
54
Signature
55
PART
I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(millions,
except per common share data)
Sept.
28,
2008
Sept.
30,
2007
Sept.
28,
2008
Sept.
30,
2007
Revenues
11,973
11,990
35,950
35,548
Costs and expenses:
Cost of sales(a)
2,122
4,618
6,397
8,614
Selling,
informational and administrative expenses(a)
3,523
3,768
10,878
10,973
Research and
development expenses(a)
1,885
1,999
5,642
5,829
Amortization of
intangible assets
621
774
2,063
2,372
Acquisition-related
in-process research and development charges
13
--
567
283
Restructuring
charges and acquisition-related costs
366
455
1,113
2,318
Other
(income)/deductions - net
721
(260)
221
(1,149)
Income from
continuing operations before provision/(benefit) for taxes on income and
minority interests
2,722
636
9,069
6,308
Provision/(benefit)
for taxes on income
463
(161)
1,251
800
Minority
interests
18
Income from
continuing operations
2,253
796
7,800
5,502
Discontinued
operations:
Gain/(loss)
from discontinued operations - net of tax
--
(4)
--
Gains/(losses)
on sales of discontinued operations - net of tax
24
(35)
42
(82)
Discontinued
operations - net of tax
25
(35)
38
(82)
Net income
2,278
761
7,838
5,420
Earnings per common share - basic:
Income from
continuing operations
0.34
0.12
1.16
0.79
Discontinued
operations - net of tax
--
(0.01)
--
(0.01)
Net income
0.34
0.11
1.16
0.78
Earnings per common share -
diluted:
Income from
continuing operations
0.33
0.12
1.16
0.79
Discontinued
operations - net of tax
0.01
(0.01)
--
(0.01)
Net income
0.34
0.11
1.16
0.78
Weighted-average
shares used to calculate earnings per common share:
Basic
6,718
6,875
6,730
6,964
Diluted
6,736
6,894
6,750
6,986
Cash dividends paid per common
share
0.32
0.29
0.96
0.87
(a)
Exclusive of amortization of
intangible assets, except as disclosed in Note 10B. Goodwill and
Other Intangible Assets: Other Intangible Assets.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(millions
of dollars)
Sept. 28,
2008*
Dec. 31,
2007**
ASSETS
Cash and cash equivalents
1,265
3,406
Short-term investments
24,752
22,069
Accounts receivable, less allowance
for doubtful accounts
9,901
9,843
Short-term loans
849
617
Inventories
4,788
5,302
Taxes and other current assets
6,486
5,498
Assets held for sale
186
114
Total current assets
48,227
46,849
Long-term
investments and loans
8,430
4,856
Property, plant and equipment, less
accumulated depreciation
14,332
15,734
Goodwill
21,353
21,382
Identifiable
intangible assets, less accumulated amortization
18,978
20,498
Other assets,
deferred taxes and deferred charges
3,929
5,949
Total assets
115,249
115,268
LIABILITIES
AND SHAREHOLDERS' EQUITY
Short-term borrowings, including
current portion of long-term debt
9,193
5,825
Accounts payable
1,649
2,270
Dividends payable
2,163
Income taxes payable
735
1,380
Accrued compensation and related
items
1,752
1,974
Other current liabilities
8,173
8,223
Total current liabilities
21,503
21,835
Long-term debt
7,152
7,314
Pension benefit
obligations
2,425
2,599
Postretirement
benefit obligations
1,747
1,708
Deferred taxes
5,824
7,696
Other taxes
payable
6,594
6,246
Other
noncurrent liabilities
2,513
2,746
Total liabilities
47,758
50,144
Minority interests
156
114
Preferred stock
76
93
Common stock
443
442
Additional
paid-in capital
70,162
69,913
Employee
benefit trust, at fair value
(432)
(550)
Treasury stock
(57,389)
(56,847)
Retained
earnings
53,175
49,660
Accumulated
other comprehensive income
1,300
2,299
Total shareholders' equity
67,335
65,010
Total liabilities and shareholders'
equity
115,249
115,268
* Unaudited.
** Condensed from audited
financial statements.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine
Months Ended
(millions
of dollars)
Sept. 28,
2008
Sept. 30,
2007
Operating
Activities:
Net income
7,838
5,420
Adjustments to
reconcile net income to net cash provided by operating activities:
Depreciation
and amortization
3,912
4,084
Share-based
compensation expense
263
335
Acquisition-related
in-process research and development charges
567
283
Intangible
asset impairments and other associated non-cash charges
--
2,220
Deferred taxes
from continuing operations
580
(1,969)
Other non-cash
adjustments
649
393
Changes in
assets and liabilities (net of businesses acquired and divested)
(1,544)
(1,180)
Net cash provided by operating
activities
12,265
9,586
Investing Activities:
Purchases of
property, plant and equipment
(1,312)
(1,218)
Purchases of
short-term investments
(22,369)
(16,606)
Proceeds from
sales and redemptions of short-term investments
20,642
23,426
Purchases of
long-term investments
(5,292)
(1,406)
Proceeds from
sales and redemptions of long-term investments
639
173
Purchases of
other assets
(36)
(93)
Acquisitions,
net of cash acquired
(962)
(464)
Other investing
activities
(1,365)
(218)
Net cash (used in)/provided by
investing activities
(10,055)
3,594
Financing Activities:
Increase in
short-term borrowings, net
31,035
130
Principal
payments on short-term borrowings
(28,518)
(744)
Proceeds from
issuances of long-term debt
605
1,243
Principal
payments on long-term debt
(561)
(61)
Purchases of
common stock
(500)
(7,494)
Cash dividends
paid
(6,409)
(6,021)
Stock option
transactions and other
41
537
Net cash used
in financing activities
(4,307)
(12,410)
Effect of
exchange-rate changes on cash and cash equivalents
(44)
14
Net
(decrease)/increase in cash and cash equivalents
(2,141)
784
Cash and cash
equivalents at beginning of period
3,406
1,827
Cash and cash
equivalents at end of period
1,265
2,611
Supplemental
Cash Flow Information:
Cash paid
during the period for:
Income taxes
1,707
4,207
Interest
541
465
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of
Presentation
We prepared the condensed
consolidated financial statements following the requirements of the Securities
and Exchange Commission (SEC) for interim reporting. As permitted under those
rules, certain footnotes or other financial information that are normally
required by accounting principles generally accepted in the United States of
America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and
operating results for subsidiaries operating outside the U.S. are as of and for
the three-month and nine-month periods ended August 24, 2008, and August 26,
2007.
Revenues, expenses, assets and
liabilities can vary during each quarter of the year. Therefore, the results
and trends in these interim financial statements may not be representative of
those for the full year.
We are responsible for the unaudited
financial statements included in this document. The financial statements
include all normal and recurring adjustments that are considered necessary for
the fair presentation of our financial position and operating results.
The information included in this
Quarterly Report on Form 10-Q should be read in conjunction with the
consolidated financial statements and accompanying notes included in Pfizer's
Annual Report on Form 10-K for the year ended December 31, 2007.
Note 2. Adoption of
New Accounting Policies
As of September 28, 2008, we adopted Financial Accounting Standards Board
(FASB) Financial Staff Position (FSP) No. 157-3, Determining the Fair Value
of a Financial Asset When the Market for That Asset is Not Active. This FSP
clarifies Statement of Financial Accounting Standards (SFAS) No. 157 and
provides an example of determining fair value when the market for a financial
asset is not active. The adoption of FASB FSP No. 157-3 did not have a significant
impact on our consolidated financial statements.
As of January 1, 2008, we adopted on
a prospective basis certain required provisions of SFAS No. 157, Fair Value
Measurements, as amended by FASB FSP No. 157-2, Effective Date of
FASB Statement No. 157. Those provisions relate to our financial assets and
liabilities carried at fair value and our fair value disclosures related to financial
assets and liabilities. SFAS 157 defines fair value, expands related disclosure
requirements and specifies a hierarchy of valuation techniques based on the
nature of the inputs used to develop the fair value measures. Fair value is defined
as the price that would be received to sell an asset or paid to transfer a
liability in an orderly transaction between market participants at the measurement
date. There are three levels of inputs to fair value measurements - Level 1,
meaning the use of quoted prices for identical instruments in active markets;
Level 2, meaning the use of quoted prices for similar instruments in active
markets or quoted prices for identical or similar instruments in markets that
are not active or are directly or indirectly observable; and Level 3, meaning the
use of unobservable inputs. Observable market data should be used when
available.
Many, but not all, of our financial
instruments are carried at fair value. For example,
substantially all of our cash equivalents, short-term investments and long-term
investments are classified as available-for-sale securities and are carried at
fair value, with unrealized gains and losses, net of tax, reported in Other
comprehensive income. Derivative financial instruments are carried
at fair value, with changes in fair value reported in various balance sheet
categories (see both Note 10 D. Financial Instruments: Derivative Financial
Instruments and Hedging Activities in our Annual Report on Form 10-K for
the year ended December 31, 2007, and Note 8C. Financial Instruments:
Derivative Financial Instruments and Hedging Activities in this Quarterly
Report) and ultimately, in Other (income)/deductions - net. Virtually
all of our valuation measurements are Level 2 measurements. The adoption of
SFAS 157 did not have a significant impact on our consolidated financial
statements. We did not elect to adopt SFAS 157 for acquired nonfinancial assets
and assumed nonfinancial liabilities.
Emerging Issues Task Force (EITF)
Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or
Services to Be Used in Future Research and Development Activities, became
effective for new contracts entered into on or after January 1, 2008. EITF
Issue No. 07-3 requires that non-refundable advance payments for goods and
services that will be used in future research and development (R&D)
activities be expensed when the R&D activity has been performed or
when the R&D goods have been received rather than when the payment is made.
The adoption of EITF Issue No. 07-3 did not have a significant impact on our consolidated
financial statements.
Note 3. Acquisitions
During the first nine months of 2008
and 2007, we acquired the following:
In the second quarter of 2008, we
acquired Encysive Pharmaceuticals Inc. (Encysive), a biopharmaceutical
company, whose main product (Thelin), for the treatment of pulmonary arterial
hypertension, is commercially available in much of the E.U., is approved in
certain other markets, and is under review by the Food and Drug
Administration (FDA). The cost of acquiring Encysive, through a tender offer
and subsequent merger, was approximately $200 million, including
transaction costs. Upon our acquisition of Encysive, Encysive's change of
control repurchase obligations under its $130 million, 2.5% convertible
notes came into effect and, as such, Encysive repurchased the convertible
notes in consideration for their par value plus accrued interest in June 2008.
In addition, in the second quarter of 2008, we acquired Serenex, Inc.
(Serenex), a privately held biotechnology company with SNX-5422, an oral Heat
Shock Protein 90 (Hsp90) inhibitor currently in Phase I trials for the potential
treatment of solid tumors and hematological malignancies, and an extensive
Hsp90 inhibitor compound library, which has potential uses in treating cancer
and inflammatory and neurodegenerative diseases. In connection with these
acquisitions, in the first nine months of 2008, we recorded approximately $170
million in Acquisition-related in-process research and development charges
and approximately $450 million in intangible assets.
In the first quarter of 2008, we
acquired CovX, a privately held biotherapeutics company specializing in
preclinical oncology and metabolic research and the developer of a
biotherapeutics technology platform that we expect will enhance our biologic
portfolio. Also in the first quarter of 2008, we acquired all the outstanding
shares of Coley Pharmaceutical Group, Inc., (Coley), a biopharmaceutical
company specializing in vaccines and drug candidates designed to fight
cancers, allergy and asthma disorders, and autoimmune diseases, for
approximately $230 million. In connection with these and two smaller
acquisitions related to Animal Health, in the first nine months of 2008, we
recorded $398 million in Acquisition-related in-process research and
development charges.
In the first quarter of 2007, we
acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical
company with a novel technology platform for developing new protein drug
candidates, and Embrex, Inc., an animal health company that possesses a
unique vaccine delivery system known as Inovoject that improves consistency
and reliability by inoculating chicks while they are still inside the egg. In
connection with these and other small acquisitions, we recorded
$283 million in Acquisition-related in-process research and
development charges.
Note 4. Certain
Charges
A. Product Litigation -
Celebrex and Bextra
In the third quarter of 2008, we
reached agreements in principle to resolve the pending U.S. consumer fraud
purported class action cases and more than 90% of the known U.S. personal injury
claims involving Celebrex and Bextra, and we reached agreements to resolve
substantially all of the cases and claims of state attorneys general involving
Celebrex and Bextra. In connection with these actions, we have recorded charges
of approximately:
$745 million applicable
to all known U.S. personal injury claims;
$89 million applicable
to the pending U.S. consumer fraud purported class action cases; and
$60 million applicable
to agreements to resolve civil cases and claims brought by 33 states and the
District of Columbia, primarily relating to alleged Bextra promotional
practices. Under these agreements, we will make a payment to the states and
adopt compliance measures that complement policies and procedures previously
established by us.
In connection with these actions, we
recorded total litigation-related charges of approximately $900 million in Other
(income)/deductions - net in the third quarter of 2008. Virtually all of
this amount is included in Other current liabilities on the condensed consolidated
balance sheet as of September 28, 2008. Although we believe that we have
insurance coverage for a portion of the proposed personal injury settlements,
no insurance recoveries have been recorded.
We believe that the charges of approximately
$745 million will be sufficient to resolve all known U.S. personal injury
claims, including those not being settled at this time. However, additional
charges may have to be taken in the future in connection with certain pending claims
and unknown claims relating to Celebrex and Bextra.
B. Adjustment of Prior Years'
Liabilities for Product Returns
Revenues in the third quarter of 2008
include a reduction of $217 million to adjust our prior years' liabilities for
product returns. After a recent detailed review of our returns experience, we
determined that our previous methodology needed to be revised, as the lag time
between product sale and return was actually longer than we had previously
assumed. Although fully recorded in the current period, virtually all of the
adjustment relates back several years.
Since this is the correction of an
error, we performed an evaluation of the impact of this error on prior periods,
as well the impact of correcting the error on a cumulative basis in the current
quarter. As a result of that analysis, we determined that the correction of
the error in prior periods would not have been material to any individual
period and we determined that the cumulative correction was not material to our
projected results for fiscal 2008. As such, the cumulative correction was
recorded in the third quarter of 2008. We have also reviewed our expense
calculations for the prior years and determined that the expense recorded in
those years was not materially different from what would have been recorded
under our revised approach.
C. Exubera
In the third quarter of 2007, we
exited Exubera, an inhalable form of insulin for the treatment of diabetes.
Total pre-tax charges for the third quarter and first nine months of 2007 were
$2.8 billion and were included primarily in Cost of sales ($2.6
billion), Selling, informational and administrative expenses ($83
million), and Research and development expenses ($131 million). The
charges were comprised of asset write-offs of $2.2 billion (intangibles,
inventory and fixed assets) and other exit costs, primarily severance, contract
and other termination costs. As of September 28, 2008, the remaining accrual
for other exit costs is approximately $220 million. Substantially all of this cash
spending is expected to be completed in 2009.
Note 5. Cost-Reduction
Initiatives
The costs incurred in connection with
our cost-reduction initiatives, which began in early 2005, follow:
Three
Months Ended
Nine
Months Ended
(millions
of dollars)
Sept. 28,
2008
Sept. 30,
2007
Sept. 28,
2008
Sept. 30,
2007
Implementation
costs(a)
378
373
1,140